Both Rezūm® and Urolift® are relatively new treatments for BPH, as countries begin reimbursing for these treatments, the market will grow significantly.” — Dr. Kamran Zamanian, Senior Partner and CEO ...
Zacks Investment Research on MSN
Should you retain Teleflex stock in your portfolio now?
Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...
PLEASANTON, Calif. (KGO) -- A Bay Area company believes it has a solution for an uncomfortable problem that affects an estimated 37 million men in the U.S. alone. If you're of a certain age, chances ...
Needham analysts said Teleflex’s inability to secure a price above the low end of their expectations could reflect “the ...
PLEASANTON, Calif.--(BUSINESS WIRE)--NeoTract, Inc., today announced that the UK’s National Institute for Health and Clinical Excellence (NICE) has issued an interventional Procedure Guidance (IPG) ...
NeoTract touted study results in the official journal of The American Urological Association that the company claims show that its UroLift device enabling minimally invasive treatment for an enlarged ...
PLEASANTON, Calif.--(BUSINESS WIRE)--NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that the European Association of Urology (EAU) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback